KOSDAQBiotech & Pharma340450

GC Genome

₩7,880▲ 3.41%2026-11-18 close
Market Cap
₩186.4B
Turnover
₩1.9B
Volume
240K
Shares out.
23.7M
PER
46.2×
PBR
2.3×
EPS
₩185
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

GC Genome: Operating profit up, net income down

GC Genome's revenue and operating profit rose from the prior quarter in the third quarter of 2026, but attributable net income has fallen for three straight quarters. Whether operating gains reach the bottom line is the central question.

  1. 1

    Third-quarter 2026 revenue was KRW 8.94 billion and operating profit was KRW 852 million, with operating profit up 10.3% from a year earlier.

  2. 2

    Attributable net income fell to KRW 255 million in the same quarter, down 82.2% from a year earlier.

  3. 3

    For 2025, operating profit (KRW 1.24 billion) and attributable net income (KRW 4.04 billion) both turned positive from 2024 losses.

  4. 4

    The company said cash holdings reached KRW 41.8 billion at the end of the third quarter, up from about KRW 40.1 billion at the end of 2025.

  5. 5

    In the US, preparation of an FDA Breakthrough Device Designation application for the pancreatic cancer early-detection test PancSight is the key variable for overseas expansion.

02

Business structure

GC Genome is a specialist diagnostics company focused on liquid biopsy and clinical genome analysis. Its core products are the non-invasive prenatal test G-NIPT and the multi-cancer early screening test ai-CANCERCH, and the company said sales growth of these two products drove recent revenue gains.

Its business spans obstetric testing, cancer testing and genetic rare disease testing, and the company described revenue growth across these existing businesses.

The revenue base is domestic test services, and the company is channeling that cash generation into R&D and overseas expansion. ai-CANCERCH is in the stage of widening the cancer types it screens and developing follow-on tests. G-NIPT is pursuing overseas entry.

The pancreatic cancer early-detection test PancSight is in development for the US market, and the company is preparing an FDA Breakthrough Device Designation application. Cash holdings at the end of the third quarter of 2026 were KRW 41.8 billion, which serves as funding for R&D and overseas investment.

Prenatal and cancer screening tests depend on referral and screening flows at hospitals and health check centers, so domestic distribution channels and test reliability are central to competitiveness. GC Genome is moving through overseas regulatory steps on the back of its domestic test business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.8B₩800M8.7%
2025Q4₩8.1B₩200M2.5%
2026Q1₩7.4B₩100M1.9%
2026Q2₩8.3B₩400M5.2%
2026Q3₩8.9B₩900M9.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩25.9B-₩1.2B-₩1.3B−4.8%−3.8%22.8%
2025₩31.5B₩1.2B₩4B3.9%5.2%8.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual results show a shift from losses in 2024 to profits in 2025. Revenue rose 21.8% from KRW 25.9 billion in 2024 to KRW 31.5 billion in 2025.

Operating profit turned positive, from an operating loss of KRW 1.23 billion in 2024 to operating profit of KRW 1.24 billion in 2025, and the operating margin moved from -4.8% to 3.9%.

Attributable net income turned positive, from a net loss of KRW 1.26 billion in 2024 to attributable net income of KRW 4.04 billion in 2025.

Net income moved in the same direction over the same period, from a net loss of KRW 1.26 billion to net income of KRW 4.04 billion, and because the attributable and total figures match in both years, the effect of non-controlling interests does not show up in these two years.

On the balance sheet, the debt-to-equity ratio fell from 22.8% in 2024 to 8.1% in 2025, and total equity of KRW 78.3 billion at the end of 2025 is entirely attributable to shareholders of the parent, against total liabilities of KRW 6.35 billion.

Operating cash flow rose from KRW 378 million in 2024 to KRW 1.3 billion in 2025. The quarterly picture is mixed in direction. Fourth-quarter 2025 revenue of KRW 8.08 billion fell 8.6% from the prior quarter and operating profit fell 74.0% to KRW 201 million, yet attributable net income rose 66.3% to KRW 2.39 billion.

The gap between operating profit and attributable net income was wide in that quarter, so non-operating items may have played a large role. First-quarter 2026 revenue of KRW 7.44 billion marked the low point, with operating profit of KRW 140 million.

Second-quarter revenue recovered to KRW 8.29 billion and operating profit rose to KRW 433 million. Third-quarter revenue reached KRW 8.94 billion and operating profit KRW 852 million, up 1.2% and 10.3% year on year respectively.

According to company statements, the third-quarter operating margin was 9.5%, compared with 8.7% a year earlier.

Attributable net income, however, was KRW 814 million in the first quarter of 2026, KRW 781 million in the second and KRW 255 million in the third, a decline for three straight quarters, and the third quarter was down 82.2% year on year.

Per company statements, cumulative revenue for the first three quarters of 2026 was KRW 24.7 billion, up 5.1%, and cumulative operating profit was KRW 1.4 billion, up 37.6%. Attributable net income for the last four quarters totals KRW 4.24 billion.

05

Industry analysis

The genetic testing market is structured so that results move with testing demand from hospitals and health check centers, as in prenatal and cancer screening. The company said it is entering the seasonal peak of domestic health check demand in the second half.

That suggests annual revenue can skew toward the second half, which is a reference point when reviewing quarterly distribution. The declines in revenue over the fourth quarter of 2025 and the first quarter of 2026 can be read alongside this seasonality, though a single cause is hard to pin down.

In competition, several diagnostics companies operate in domestic liquid biopsy and genetic testing, and GC Genome holds product positions in the specific areas of prenatal testing and multi-cancer early screening.

Overseas competition is characterized by high regulatory barriers, including FDA procedures and local sample validation in the US. The company said it is recruiting US residents for sample collection and performance validation, and plans to submit a Breakthrough Device Designation application.

It described domestic cash generation as funding for these validation and regulatory steps. Within the biopharma sector, GC Genome's revenue base is test services rather than therapeutics, so its earnings structure differs from therapeutics-focused companies. Its business model and scale differ from large biopharma peers, which makes direct comparison difficult.

06

Outlook

The outlook the company has presented is largely directional. In announcing preliminary first-half 2026 results in August 2026, the CEO said that with the domestic health check season concentrated in the second half, he expects growth to widen.

That direction matches the rise in third-quarter 2026 operating profit, but attributable net income fell over the same period, so growth in operating profit and in the bottom line diverged. ai-CANCERCH is in the stage of widening the cancer types it screens and developing follow-on tests.

G-NIPT is pursuing overseas entry. In the US, the company is pursuing an FDA Breakthrough Device Designation for ai-CANCERCH, and the pancreatic cancer early-detection test PancSight is in development with a designation application being prepared.

The company said it is collecting samples from US residents and validating performance. However, the timing of the designation process has not been presented as a public schedule.

Overseas revenue would only be reflected in results after designation and local validation, so the uncertainty in this outlook is larger than in domestic test revenue.

The next checkpoint is the preliminary fourth-quarter 2026 result, which can be compared with fourth-quarter 2025 revenue of KRW 8.08 billion and operating profit of KRW 201 million. The 2026 annual report will then provide the audited full-year results and a regular checkpoint on the business.

07

Valuation

PER
46.2×
PBR
2.3×
ROE
5.5%
EPS
₩185
BPS
₩3,665
Dividend per share
₩0

The current earnings multiple, measured against attributable net income of KRW 4.24 billion over the last four quarters, shows a market capitalization that is large relative to earnings. The multiple sits in a high range on earnings, and it will shift with the pace at which operating profit and net income recover.

On a book-value basis, total equity of KRW 78.3 billion at the end of 2025 is entirely attributable to shareholders of the parent, and the stock is trading at a premium to net assets.

The move from a loss in 2024 to profit in 2025 created an earnings base, but net income has declined in 2026, so the share price level has diverged from the earnings trend. The dividend yield is below the industry average, so cash returns to shareholders are limited.

Cash holdings of KRW 41.8 billion are a meaningful share of the market capitalization, and how that cash is deployed into overseas investment and R&D could change the asset structure. Valuation is best read alongside the direction of earnings and changes in the balance sheet.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Optionality from overseas entry

The company is pursuing an FDA Breakthrough Device Designation for ai-CANCERCH, and the pancreatic cancer early-detection test PancSight is in development for US market entry. Overseas entry for G-NIPT is also being pursued.

The company describes ongoing sample collection and performance validation among US residents, which could add an overseas revenue axis on top of domestic test sales.

Direction of profitability improvement

Operating profit moved from an operating loss of KRW 1.23 billion in 2024 to operating profit of KRW 1.24 billion in 2025, and the operating margin rose from -4.8% to 3.9%. According to company statements, the third-quarter 2026 operating margin was 9.5%, compared with 8.7% a year earlier.

The company said cumulative operating profit for the first three quarters rose 37.6%. On an operating basis, the direction of improved profitability is consistent across the reported periods.

Financial capacity

Total liabilities at the end of 2025 were KRW 6.35 billion, and the debt-to-equity ratio fell from 22.8% in 2024 to 8.1% in 2025. Cash holdings at the end of the third quarter were KRW 41.8 billion, up from about KRW 40.1 billion at the end of 2025.

Operating cash flow also rose from KRW 378 million in 2024 to KRW 1.3 billion in 2025, which leaves room to fund R&D and overseas investment without relying heavily on external financing.

09

Bear factors

Weakness in net income

Attributable net income peaked at KRW 2.39 billion in the fourth quarter of 2025 and then fell to KRW 814 million in the first quarter of 2026, KRW 781 million in the second and KRW 255 million in the third, a decline for three straight quarters. Third-quarter attributable net income was down 82.2% year on year. Operating profit rose while net income fell, so non-operating items and expense lines need to be read together.

Slower revenue growth

Third-quarter 2026 revenue of KRW 8.94 billion rose only 1.2% year on year. According to company statements, cumulative revenue for the first three quarters rose 5.1%. Revenue fell for two consecutive quarters from the fourth quarter of 2025 through the first quarter of 2026, before rising for two straight quarters. The pace of top-line expansion is more gradual than the growth in operating profit.

A share price high relative to earnings

The market capitalization is large relative to attributable net income of KRW 4.24 billion over the last four quarters. The shares trade at a premium to net assets, so a slower earnings recovery would increase pressure on the multiple. The dividend yield is below the industry average, which limits cash returns to shareholders.

10

Risk factors

Regulation and overseas entry

FDA Breakthrough Device Designation depends on the application process and review outcome, so designation could be delayed or not granted. Local validation and regulatory work in the US require time and cost, which could weigh on near-term earnings. Until US performance is demonstrated, overseas revenue will not appear in the financial statements.

Earnings volatility

Attributable net income has swung widely from quarter to quarter. In the fourth quarter of 2025, attributable net income of KRW 2.39 billion was recorded against operating profit of KRW 201 million, which suggests non-operating factors may have had a large effect.

Gaps like this make it hard to interpret the link between operating performance and final profit on a quarterly basis.

Concentration in test products and seasonality

Revenue relies heavily on sales of core test products such as G-NIPT and ai-CANCERCH. The company pointed to the seasonal peak in health check demand in the second half, which can produce uneven revenue across quarters. A change in demand or reimbursement environment for a specific test could move overall results.

11

What to watch next

  1. After December 2026 (timing undetermined)

    Whether the FDA Breakthrough Device Designation application for ai-CANCERCH and the PancSight application are submitted and their progress. Designation would determine when overseas revenue could begin to be reflected.

  2. January to February 2027 (expected timing of preliminary results)

    Compare preliminary fourth-quarter 2026 results with fourth-quarter 2025 revenue of KRW 8.08 billion and operating profit of KRW 201 million. Whether the three-quarter streak of declines in attributable net income ends is the point to check.

  3. March 31, 2027 (statutory filing deadline)

    Check audited full-year 2026 results in the annual report. Confirm whether the 2025 move to annual profit held in 2026 and what drove the decline in attributable net income, as disclosed in the filing.

  4. May 15, 2027 (statutory deadline for the first-quarter report)

    Compare first-quarter 2027 revenue and operating profit with first-quarter 2026 revenue of KRW 7.44 billion and operating profit of KRW 140 million. This checks whether revenue growth since the second quarter of 2026 persists outside the seasonal peak.

12

Overall view

GC Genome swung from an operating loss in 2024 to an operating profit in 2025, and its operating profit in the third quarter of 2026 also rose from a year earlier. Revenue in 2025 was KRW 31.5 billion, up 21.8% from the previous year, which expanded its revenue base.

However, net income attributable to controlling shareholders has fallen for three consecutive quarters since peaking in the fourth quarter of 2025, so the key issue is whether the operating improvement carries through to net income.

Bullish factors include cash-generating power from its testing products, KRW 41.8 billion in cash holdings, and its pursuit of a U.S. FDA designation. Bearish factors include the decline in net income, third-quarter revenue growth of 1.2%, and a market capitalization that is large relative to earnings.

The two sets of factors should be weighed equally, and neither side decides the conclusion. The next checkpoints are the preliminary fourth-quarter 2026 results, the 2026 annual report, and the progress of the U.S. FDA designation application. This report is intended for informational purposes only and contains no investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. fnnews.com
  2. medipana.com
  3. kr.investing.com
  4. betanews.net
  5. thebionews.net
  6. ziksir.com
  7. pinpointnews.co.kr
  8. inthenews.co.kr
  9. thefairnews.co.kr
  10. m.news.nate.com
  11. ebn.co.kr
  12. pharmnews.com
  13. sentv.co.kr
  14. newscj.com
  15. meconomynews.com
  16. sateconomy.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis